Literature DB >> 21886301

Dual paraneoplastic syndromes: small cell lung carcinoma-related oncogenic osteomalacia, and syndrome of inappropriate antidiuretic hormone secretion: report of a case and review of the literature.

Ekamol Tantisattamo1, Roland C K Ng.   

Abstract

Acquired isolated renal phosphate wasting associated with a tumor, known as oncogenic osteomalacia or tumor-induced osteomalacia, is a rare paraneoplastic syndrome caused by overproduction of fibroblast growth factor 23. Oncogenic osteomalacia is usually associated with benign mesenchymal tumors. Syndrome of inappropriate antidiuretic hormone secretion (SIADH), on the other hand, is a common paraneoplastic syndrome caused by small cell carcinoma (SCC). Concomitant oncogenic osteomalacia and SIADH associated with SCC is very rare with only 4 other cases reported in the literature. The authors report a case of small cell lung cancer (SCLC)-related renal wasting hypophosphatemia and concurrent SIADH, and review the literature reporting 9 other cases of SCC associated with oncogenic osteomalacia. Almost half of reported cases of renal phosphate wasting associated with SCC concomitantly presented with SIADH. These cases had initial serum phosphorus level lower and survival periods shorter than those without SIADH. This rare combination of a dual paraneoplastic syndrome and low serum phosphorus may be a poor prognostic sign. In addition, both renal phosphate wasting and SIADH usually occur in a short period of time before identification of SCC. Therefore, renal wasting hypophosphatemia with concomitant SIADH/hyponatremia should prompt a search for SCC rather than a benign mesenchymal tumor.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21886301      PMCID: PMC3158371     

Source DB:  PubMed          Journal:  Hawaii Med J        ISSN: 0017-8594


  24 in total

1.  [Rickets following bone tumor].

Authors:  A PRADER; R ILLIG; E UEHLINGER; G STALDER
Journal:  Helv Paediatr Acta       Date:  1959-12

2.  Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia.

Authors:  N Ito; Y Shimizu; H Suzuki; T Saito; T Okamoto; M Hori; M Akahane; S Fukumoto; T Fujita
Journal:  J Intern Med       Date:  2010-10       Impact factor: 8.989

3.  Acquired hypophosphatemic osteomalacia associated with multiple myeloma.

Authors:  Javier Narvaez; Eva Domingo-Domenech; José A Narvaez; Joan M Nolla; José Valverde
Journal:  Joint Bone Spine       Date:  2005-01-26       Impact factor: 4.929

4.  Oncogenic osteomalacia associated with prostate cancer.

Authors:  D M Reese; P J Rosen
Journal:  J Urol       Date:  1997-09       Impact factor: 7.450

5.  Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia.

Authors:  Yuji Yamazaki; Ryo Okazaki; Minako Shibata; Yukihiro Hasegawa; Kohei Satoh; Toshihiro Tajima; Yasuhiro Takeuchi; Toshiro Fujita; Kazuhiko Nakahara; Takeyoshi Yamashita; Seiji Fukumoto
Journal:  J Clin Endocrinol Metab       Date:  2002-11       Impact factor: 5.958

6.  Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia.

Authors:  Kenneth B Jonsson; Richard Zahradnik; Tobias Larsson; Kenneth E White; Toshitsugu Sugimoto; Yasuo Imanishi; Takehisa Yamamoto; Geeta Hampson; Hiroyuki Koshiyama; Osten Ljunggren; Koichi Oba; In Myung Yang; Akimitsu Miyauchi; Michael J Econs; Jeffrey Lavigne; Harald Jüppner
Journal:  N Engl J Med       Date:  2003-04-24       Impact factor: 91.245

Review 7.  Syndrome of inappropriate antidiuretic hormone associated with chemotherapy-induced tumour lysis in small-cell lung cancer: case report and literature review.

Authors:  S L Vanhees; R Paridaens; J F Vansteenkiste
Journal:  Ann Oncol       Date:  2000-08       Impact factor: 32.976

8.  Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1.

Authors:  Fadil M Hannan; Nicholas A Athanasou; James Teh; Christopher L M H Gibbons; Brian Shine; Rajesh V Thakker
Journal:  Eur J Endocrinol       Date:  2008-02       Impact factor: 6.664

9.  Oncogenic osteomalacia: two case reports with surprisingly different outcomes.

Authors:  Roberto Seijas; Oscar Ares; Judit Sierra; Manuel Pérez-Dominguez
Journal:  Arch Orthop Trauma Surg       Date:  2009-01-06       Impact factor: 3.067

10.  Case report: renal phosphate wasting, syndrome of inappropriate antidiuretic hormone, and ectopic corticotropin production in small cell carcinoma.

Authors:  J L Shaker; R C Brickner; A B Divgi; H Raff; J W Findling
Journal:  Am J Med Sci       Date:  1995-07       Impact factor: 2.378

View more
  2 in total

Review 1.  Progress in the management of limited-stage small cell lung cancer.

Authors:  Arya Amini; Lauren A Byers; James W Welsh; Ritsuko U Komaki
Journal:  Cancer       Date:  2013-12-10       Impact factor: 6.860

2.  Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma.

Authors:  David E Leaf; Renata C Pereira; Hasan Bazari; Harald Jüppner
Journal:  J Clin Endocrinol Metab       Date:  2013-02-07       Impact factor: 5.958

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.